AstraZeneca

AstraZeneca EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of AstraZeneca (AZN.L) as of Nov 4, 2026 is 22.01. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 27.12 — a change of -18.81% (lower).

EV/OCF

22.01

YoY

-18.81%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of AstraZeneca is 2025 22.01 . EV/OCF (Enterprise Value to Operating Cash Flow) of AstraZeneca was 2024 27.12 . It decreases by -18.81% lower compared to the previous year.

The AstraZeneca EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
118.60 USD
Jan 1, 2019
104.07 USD
Jan 1, 2020
64.47 USD
Jan 1, 2021
53.89 USD
Jan 1, 2022
32.62 USD
Jan 1, 2023
30.90 USD
Jan 1, 2024
27.12 USD
Jan 1, 2025
22.01 USD
The AstraZeneca EV/OCF history
YEAREV/OCFYoY
22.01-18.81%
27.12-12.25%
30.90-5.27%
32.62-39.47%
53.89-16.40%
64.47-38.05%
104.07-12.25%
118.60+36.79%
86.70+16.70%
74.30-19.06%
91.80+114.95%
42.71—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AstraZeneca Stock analysis

What does AstraZeneca do? AstraZeneca PLC is a globally operating pharmaceutical company with its headquarters in England. The company was founded in 1999 through the merger of the Swedish company Astra AB and the British Zeneca Group PLC. Today, AstraZeneca employs more than 70,000 people and operates in over 100 countries. AstraZeneca specializes in the development, manufacturing, and marketing of pharmaceutical products. The company focuses primarily on oncology, cardiovascular and metabolic diseases, respiratory diseases, and autoimmune diseases. AstraZeneca is divided into various business segments. The oncology segment is a major focus of the company. Here, medications for various types of cancer are developed and manufactured. One particularly well-known product is the breast cancer medication Tamoxifen. In the cardiovascular and metabolic diseases segment, AstraZeneca offers various medications for heart and circulatory diseases as well as diabetes. One of the most well-known medications is Crestor, which is used to lower cholesterol levels. Another important area for AstraZeneca is respiratory diseases. Medications for the treatment of asthma and chronic obstructive pulmonary disease (COPD) are developed and manufactured here. The medication Pulmicort is particularly well-known among asthma patients. Finally, AstraZeneca is also active in the field of autoimmune diseases. Medications against lupus erythematosus and rheumatoid arthritis are developed and manufactured here. AstraZeneca strives to improve healthcare worldwide through research and development of new medications. The company works closely with universities and research institutions and invests billions of dollars annually in research and development. AstraZeneca also pursues a sustainable business strategy and emphasizes acting environmentally and socially responsibly. The company is committed to reducing CO2 emissions and minimizing waste production. Over the years, AstraZeneca has received numerous awards and prizes, including the Sunday Times Innovation Award of the Decade, the Fierce Biotech Award for the medication Tagrisso, and the Prix Galien USA Award for Crestor. AstraZeneca aims to develop innovative medications that improve the lives of patients and advance healthcare worldwide. The company believes in a sustainable business strategy and actively promotes environmental and social responsibility. AstraZeneca will remain an important player in the global pharmaceutical industry in the future. AstraZeneca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AstraZeneca stock

EV/OCF (Enterprise Value to Operating Cash Flow) of AstraZeneca is 22.01 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of AstraZeneca changed from 27.12 to 22.01, representing a -18.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) AstraZeneca since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s AstraZeneca with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — AstraZeneca

All Key Metrics — AstraZeneca